Free Trial
NASDAQ:ADXS

Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

$0.0012
-0.14 (-99.15%)
(As of 07/26/2024 ET)
Today's Range
$0.0012
$0.0012
50-Day Range
$0.00
$0.32
52-Week Range
$0.00
$1.49
Volume
633 shs
Average Volume
16,875 shs
Market Capitalization
$51,156.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ADXS stock logo

About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

ADXS Stock Price History

ADXS Stock News Headlines

How a $0.25 cent option contract makes my top traders feel
If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…
Immunome: An Oncology Powerhouse In The Making
IMNM Oct 2024 22.500 call
IMNM Oct 2024 25.000 call
IMNM Oct 2024 25.000 put
How a $0.25 cent option contract makes my top traders feel
If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…
IMNM Oct 2024 45.000 call
Ayala Pharmaceuticals Inc Ordinary Shares ADXS
See More Headlines
Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/09/2021
Today
7/26/2024
Next Earnings (Estimated)
7/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADXS
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-48,070,000.00
Pretax Margin
-399,876.94%

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
($2.06) per share

Miscellaneous

Free Float
42,364,000
Market Cap
$51,156.00
Optionable
Not Optionable
Beta
1.55
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Ruth Ben Yakar Ph.D. (Age 54)
    Chief Exec. Officer
  • Dr. Stela Gangrenovitch Ph.D.
    Co-Founder, Chief Scientist Officer and Director
  • Mr. Mark Gengrinovitch LLB
    Co-Founder, Chief Financial Officer and Director

ADXS Stock Analysis - Frequently Asked Questions

How have ADXS shares performed this year?

Ayala Pharmaceuticals' stock was trading at $0.6670 at the beginning of the year. Since then, ADXS stock has decreased by 99.8% and is now trading at $0.0012.
View the best growth stocks for 2024 here
.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) issued its earnings results on Thursday, September, 9th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The company had revenue of $0.25 million for the quarter.

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX) and

This page (NASDAQ:ADXS) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners